Biobeat

Biobeat is a med-tech company providing FDA-cleared, cuffless blood pressure monitoring. The small, non-invasive sensor is placed onto the patient’s chest for 24 hours, and the measurements are taken through our proprietary patented PPG sensor. The technology not only allows for blood pressure to be taken, but also extracts heart rate, and cardiac output. The device and automated platform deliver a detailed report to the clinician, immediately after the patient has completed the test. This allows for quick evaluation and treatment plans, and also enables physicians to make proper adjustments on current treatment plans based on the quantitative measures and trends that the blood pressure monitoring solution provides. The Biobeat sensor eliminates white coat and masked hypertension by using a cuffless test. White coat hypertension is a common barrier in ABPM testing, as patients often become stressed when the cuff inflates. However, with Biobeat, patients often forget they are wearing the sensor and do not feel when the readings are being taken. This allows them to go about their daily lives without interruption.

Biobeat has raised $18.6M in total funding across 6 rounds. The company is currently at the A stage. Key investors include Best Buy Health, Infinity Medical, Menomadin Foundation.

Biobeat was founded in 2016 by Arik Ben Ishay (CEO), Johanan May (Co-founder & CTO), Israel Sarussi (Co-founder & VP R&D).

Biobeat operates in Health Tech & Life Sciences, Medical Devices, Medical Monitors, Digital Healthcare, Patient Remote Monitoring, with core technologies in Semiconductors & Electronics, Wearables, Artificial Intelligence, Machine Learning, Sensing, Biometrics. Target customers: Healthcare & Life Sciences, Life Sciences, Medical Devices Industry, Healthcare, Providers.

Biobeat is based in Ef'al St 22, Petah Tikva, Israel, Center District. The company also has offices abroad.